Eric Greig

Practice Areas

Eric Greig advises clients on market access and reimbursement strategies across the medical device, pharmaceutical, digital health, biotechnology, clinical laboratory, and healthcare services sectors.

Mr. Greig leverages his track record of success in bet-the-company regulatory matters, as well as his extensive experience with health payment systems and innovative solutions, to guide clients across the healthcare and life sciences industry on:

• Development and execution of market access strategies for new and existing technologies

• Advocacy with Congress and federal and state agencies, including the Centers for Medicare and Medicaid Services (CMS)

• Medicare and Medicaid coverage, coding, and reimbursement matters

• Compliance with billing policies

• Federal and state fraud and abuse laws, including development of compliance programs

• Federal and state “sunshine” laws

• Complex litigation matters, including government audits and investigations, qui tam lawsuits, and other matters involving the HHS Office of Inspector General (OIG), US Department of Justice, and CMS Center for Program Integrity

Mr. Greig also advises private equity firms, investment banks, venture capital funds, commercial lenders, and healthcare and life science companies on regulatory issues related to mergers and acquisitions, IPOs, and US financings.

Mr. Greig is a member of the American Health Law Association and the American Bar Association Health Law Section.

A recognized thought leader, Mr. Greig regularly writes and speaks on healthcare and life sciences topics. He co-authored a chapter related to Medicare and Medicaid reimbursement for off-label uses of drugs and devices in Off-Label Communications: A Guide to Sales & Marketing Compliance, published by the Food and Drug Law Institute (FDLI), and presents on healthcare regulatory and reimbursement topics at national conferences organized by leading industry organizations including AdvaMed, PhRMA, the American Health Law Association (AHLA), the Medical Device Manufacturers Association (MDMA), the 8400 Health Network, and the California Life Sciences Institute.